Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Acid-suppressing medications may be overprescribed for infants

21.10.2011
Commentary scrutinizes use of proton pump inhibitors for young children

Frequent spitting up, irritability and unexplained crying in infants are often very distressing to parents. Physicians frequently prescribe acid-suppressing drugs for these symptoms.

However, gastroesophageal reflux disease (GERD) is an uncommon cause of these symptoms in otherwise thriving infants, and in his commentary published in the Journal of Pediatrics, Dr. Eric Hassall cautions against over-diagnosis of GERD and over-prescription of acid-suppressing drugs in children under one year of age.

Dr. Hassall, a member of the division of gastroenterology at BC Children's Hospital, a professor of pediatrics at the University of British Columbia, and an advisor to the U.S. Food and Drug Administration, traces the history and current uses of acid-suppressing medication in children and infants, mostly focusing on proton pump inhibitors (PPIs). He points out that clinical studies have shown PPIs to be highly effective in children 1 to 17 years of age who have proven GERD.

In children under the age of one year, the use of these drugs has enormously increased in the last decade, a change in medical practice that Dr. Hassall says is not based in medical science. The rise of prescriptions owes a lot to direct-to-consumer advertising of pharmaceutical products, with its promotion of the misleading term "acid reflux," frequent self-misdiagnosis, and demand for medication. As Dr. Hassall observes, "it is recognized that more advertising leads to more requests by patients for advertised medicine, and more prescriptions; the term 'acid reflux' as used in the marketing of PPIs to adults, has simply trickled down to infants." He points out that most "reflux" in infants is not "acid," because stomach contents have been buffered by frequent feedings.

Randomized, controlled studies have shown that PPIs are no better than placebo for most infants with symptoms of spitting up and irritability, or unexplained crying. Dr Hassall explains that this is because the medications are frequently prescribed for symptoms that are not GERD. He emphasizes that spitting up in otherwise healthy, thriving infants is normal, and resolves with time; this is known as "physiological reflux." As infants have a limited range of responses to stimuli, it can be difficult to diagnose their cause. Irritability or unexplained crying, with or without spitting up, is often a normal developmental phenomenon especially in infants two to five months or so, less commonly thereafter. Some infants, once crying, are unable to self-calm. This improves with maturation and age. "The state of being new in the world and getting used to new bodily sensations, such as gassiness," also may contribute. When severe unexplained crying occurs in otherwise healthy infants, prevalent causes include sensitivity to cow's milk protein or other dietary components, including those that are present in breast milk. Nonpharmacological measures such as dietary changes, together with 'tincture of time' and reassurance, usually result in resolution.

As Dr. Hassall explains: "In the absence of better information and physician guidance and fed by advertising and misinformation on the Internet, parent blogs have increasingly promoted the ''my-baby-has-acid-reflux-and-needs-drugs'' concept. Parents, concerned by their infant's symptoms of apparent suffering, take their concern to doctors, who very frequently comply and prescribe acid-suppressing medications for symptoms and signs that in most cases are not GERD. GERD-mania is in full cry, so to speak."

"We are medicalizing normality," Dr. Hassall asserts, "In most infants, these symptoms are 'life,' not a disease, and do not warrant treatment with drugs, which can have significant adverse effects." He explains that gastric acid is an early line of defense against infection, and important for nutrition, and by prescribing acid suppressing medications, especially PPIs, to infants without GERD, pediatricians are putting their patients at a higher risk for infections like pneumonia and gastroenteritis. The use of PPIs in infants can also lead to abnormalities in the levels of essential minerals and vitamins, such as magnesium, calcium, and vitamin B12.

Dr. Hassall encourages his fellow pediatricians to opt initially for nonpharmacological approaches, such as changes in maternal diet of breastfeeding mothers, or hypoallergenic formulas for bottle-feeding infants. However, if these fail, or if an infant has severe symptoms and is suspected of having GERD, Dr. Hassall suggests beginning treatment initially with an histamine-2-receptor antagonist (such as ranitidine or famotidine) for a time-limited period of 2-weeks. If the infant does show improvement, dosage and length of treatment can be increased if necessary, or a trial of once-daily PPI started. However, as Dr. Hassall notes, "In most cases, it is not the spitting up that should be treated. The real issue is the unexplained crying, which causes real and considerable distress and concern for parents." He goes on to explain, "Parents can hardly be blamed for becoming rattled and concerned about their crying infant. It is important to acknowledge their concerns, explain the spectrum of normal infant behavior, discuss the range of measures available, start implementation, and be available for follow-up."

Dr. Hassall is available for interview, however he is on leave from his position at BC Children's Hospital, and is currently at Sutter Pacific Medical Foundation in San Francisco, California.

Brian Kladko | EurekAlert!
Further information:
http://www.ubc.ca

More articles from Health and Medicine:

nachricht TSRI researchers develop new method to 'fingerprint' HIV
29.03.2017 | Scripps Research Institute

nachricht Periodic ventilation keeps more pollen out than tilted-open windows
29.03.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers shoot for success with simulations of laser pulse-material interactions

29.03.2017 | Materials Sciences

Igniting a solar flare in the corona with lower-atmosphere kindling

29.03.2017 | Physics and Astronomy

As sea level rises, much of Honolulu and Waikiki vulnerable to groundwater inundation

29.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>